These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Pang RW; Poon RT Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180 [TBL] [Abstract][Full Text] [Related]
5. Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan. Kudo M; Ueshima K Oncology; 2010 Jul; 78 Suppl 1():154-66. PubMed ID: 20616599 [TBL] [Abstract][Full Text] [Related]
7. Future treatment option for hepatocellular carcinoma: a focus on brivanib. Kudo M Dig Dis; 2011; 29(3):316-20. PubMed ID: 21829023 [TBL] [Abstract][Full Text] [Related]
8. Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma. Kudo M Dig Dis; 2011; 29(3):289-302. PubMed ID: 21829020 [TBL] [Abstract][Full Text] [Related]
9. Molecularly targeted therapies for hepatocellular carcinoma: sorafenib as a stepping stone. Kim HY; Park JW Dig Dis; 2011; 29(3):303-9. PubMed ID: 21829021 [TBL] [Abstract][Full Text] [Related]
10. Targeted therapy for liver cancer: updated review in 2012. Kudo M Curr Cancer Drug Targets; 2012 Nov; 12(9):1062-72. PubMed ID: 22920326 [TBL] [Abstract][Full Text] [Related]
11. Positioning and indication of sorafenib in the treatment algorithm and real practice setting: Western and eastern approach--Asian perspective. Lee JM; Han KH Oncology; 2010 Jul; 78 Suppl 1():167-71. PubMed ID: 20616600 [TBL] [Abstract][Full Text] [Related]